TDMS No. 99023 - 03 Test Type: CHRONIC Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) beta-Myrcene CAS Number: 123-35-3	Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT
	F1_Rev.2_R2	
C Number:	C99023	
Lock Date:	12/22/2004	
Cage Range:	ALL	
Date Range:	ALL	
Reasons For Removal:	ALL	

Removal Date Range:

Treatment Groups:

Study Gender:

TDMSE Version:

ALL

Both

2.0.0

Include ALL

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Disposition Summary					
Animals Initially in Study	50	50	50	50	
Early Deaths					
Dosing Accident		1		1	
Moribund Sacrifice	18	8	13	24	
Natural Death	3	5	9	25	
Survivors					
Terminal Sacrifice	29	36	28		
Animals Examined Microscopically	50	50	50	50	
LIMENTARY SYSTEM					
Esophagus	(50)	(50)	(50)	(50)	
Inflammation, Chronic			1 (2%)		
Perforation		1 (2%)		1 (2%)	
Muscularis, Periesophageal Tissue,				1 (2%)	
Hemorrhage					
Intestine Large, Cecum	(50)	(50)	(50)	(50)	
Inflammation, Chronic			1 (2%)		
Intestine Large, Colon	(50)	(50)	(50)	(50)	
Inflammation, Chronic			1 (2%)		
Parasite Metazoan	1 (2%)	1 (2%)	2 (4%)		
Intestine Large, Rectum	(50)	(50)	(50)	(48)	
Inflammation, Chronic			1 (2%)		
Parasite Metazoan	6 (12%)	4 (8%)	3 (6%)		
Ulcer				1 (2%)	
Intestine Small, Duodenum	(49)	(50)	(50)	(50)	
Intestine Small, Ileum	(50)	(50)	(50)	(50)	
Parasite Metazoan	1 (2%)				
Intestine Small, Jejunum	(50)	(50)	(50)	(50)	
Liver	(50)	(50)	(50)	(50)	
Angiectasis	2 (4%)	4 (8%)	3 (6%)		
Basophilic Focus	23 (46%)	12 (24%)	5 (10%)	2 (4%)	
Clear Cell Focus	14 (28%)	19 (38%)	9 (18%)		
Degeneration, Cystic	1 (2%)	1 (2%)			
Eosinophilic Focus	6 (12%)	5 (10%)	3 (6%)		
Fatty Change	4 (8%)	4 (8%)	2 (4%)		
Hemorrhage				1 (2%)	
Hepatodiaphragmatic Nodule	3 (6%)	3 (6%)	2 (4%)	3 (6%)	
Inflammation, Chronic	34 (68%)	36 (72%)	19 (38%)	1 (2%)	
Mixed Cell Focus	6 (12%)	1 (2%) 4 (8%)	4 (8%)		
Necrosis				4 (8%)	

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Regeneration		1 (2%)			
Bile Duct, Hyperplasia	39 (78%)	42 (84%)	39 (78%)	6 (12%)	
Centrilobular, Degeneration	3 (6%)	1 (2%)	1 (2%)	00 (000()	
Hepatocyte, Hypertrophy Serosa, Hyperplasia	1 (2%)	1 (29/)		30 (60%)	
Serosa, Inflammation, Suppurative		1 (2%)	1 (2%)		
Mesentery	(13)	(8)	(5)	(3)	
Fat. Necrosis	12 (92%)	7 (88%)	4 (80%)	3 (100%)	
Oral Mucosa	(2)	(0)	(0)	(0)	
Inflammation, Chronic	1 (50%)		(-)	(-)	
Pancreas	(50)	(50)	(50)	(50)	
Inflammation, Granulomatous	1 (2%)				
Necrosis	1 (2%)	/		- /	
Acinus, Atrophy	9 (18%)	14 (28%)	11 (22%)	5 (10%)	
Acinus, Hyperplasia	8 (16%)	7 (14%)	2 (4%)		
Artery, Inflammation, Chronic Artery, Thrombosis			1 (2%)	1 (2%)	
Duct, Cyst	2 (4%)	3 (6%)	5 (10%)	1 (2%)	
Salivary Glands	(50)	(50)	(50)	(48)	
Atrophy	(00)	(88)	(88)	1 (2%)	
Cyst		1 (2%)		(=,0)	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Erosion	1 (2%)			3 (6%)	
Fibrosis			1 (2%)		
Inflammation, Chronic Active	5 (10%)	3 (6%)	12 (24%)	27 (54%)	
Ulcer	2 (4%)	2 (4%)	5 (10%)	18 (36%)	
Serosa, Hyperplasia	(50)	(50)		1 (2%)	
Stomach, Glandular Inflammation, Chronic	(50) 3 (6%)	(50) 7 (14%)	(50) 2 (4%)	(50)	
Mineralization	3 (6%) 1 (2%)	7 (14%)	2 (4%) 1 (2%)		
Ulcer	1 (2%)	2 (4%)	1 (2%)	1 (2%)	
Epithelium, Ectasia	14 (28%)	27 (54%)	33 (66%)	14 (28%)	
Epithelium, Hyperplasia	1 (2%)	2 (4%)	1 (2%)	(2070)	
CARDIOVASCULAR SYSTEM					
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	39 (78%)	43 (86%)	42 (84%)	38 (76%)	
Atrium, Thrombosis	2 (4%)		2 (4%)	,	
Endocardium, Hyperplasia				1 (2%)	
Epicardium, Hyperplasia				1 (2%)	
Myocardium, Mineralization			1 (2%)	1 (2%)	
Valve, Thrombosis			2 (4%)		

Route: GAVAGE

Test Type: CHRONIC

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
NDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Hyperplasia	3 (6%)	5 (10%)	9 (18%)	1 (2%)	
Necrosis		2 (4%)		1 (2%)	
Vacuolization Cytoplasmic	13 (26%)	16 (32%)	15 (30%)	7 (14%)	
Capsule, Hyperplasia Adrenal Medulla	(50)	1 (2%) (50)	(50)	(50)	
Hyperplasia	(50) 9 (18%)	(50) 9 (18%)	(50) 13 (26%)	(50)	
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	1 (2%)	(00)	(88)	(00)	
Parathyroid Gland	(45)	(47)	(48)	(45)	
Hyperplasia			1 (2%)	2 (4%)	
Pituitary Gland	(50)	(49)	(50)	(50)	
Angiectasis	8 (16%)	8 (16%)	9 (18%)	1 (2%)	
Cyst Pars Distalis, Hyperplasia	6 (12%) 15 (30%)	9 (18%) 11 (22%)	5 (10%) 10 (20%)	2 (4%) 4 (8%)	
Thyroid Gland	(50)	(50)	(50)	(49)	
Cyst	1 (2%)	(00)	1 (2%)	(10)	
Inflammation, Granulomatous				1 (2%)	
C-cell, Hyperplasia	20 (40%)	18 (36%)	15 (30%)	1 (2%)	
Follicle, Hyperplasia	4 (8%)	2 (4%)	3 (6%)		
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
Epididymis	(50)	(50)	(50)	(48)	
Granuloma Sperm	(/	x · · · /	1 (2%)	· · /	
Inflammation, Chronic			1 (2%)		
Vacuolization Cytoplasmic, Focal	1 (2%)	(50)	(50)		
Preputial Gland Atrophy	(50) 1 (2%)	(50)	(50)	(47)	
Cyst	1 (2%)				
Hyperplasia	1 (2%)	2 (4%)			
Inflammation, Chronic	42 (84%)	44 (88%)	43 (86%)	36 (77%)	
Prostate	(50)	(50)	(50)	(50)	
Atrophy				1 (2%)	
Hyperplasia	7 (14%)	3 (6%)	6 (12%)	1 (2%)	
Inflammation, Chronic	4 (8%)	6 (12%)	8 (16%)	6 (12%)	
Inflammation, Chronic Active	1 (2%)				

DMS No. 99023 - 03 Test Type: CHRONIC Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE	Date Report Requested: 08/15/200 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT			
FISCHER 344 RATS MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Necrosis Seminal Vesicle Atrophy Testes Interstitial Cell, Hyperplasia	(50) (50) 6 (12%)	(50) (50) 2 (4%)	(50) (50) 2 (4%)	1 (2%) (50) 1 (2%) (48) 9 (19%)	
HEMATOPOIETIC SYSTEM					
Bone Marrow Hyperplasia Lymph Node Mediastinal, Ectasia Mediastinal, Hemorrhage Mediastinal, Hyperplasia, Lymphoid Mediastinal, Pigmentation, Hemosiderin Lymph Node, Mandibular Lymph Node, Mesenteric Pigmentation, Hemosiderin Spleen Atrophy Congestion Fibrosis Hematopoietic Cell Proliferation Infarct Necrosis, Focal Thymus Atrophy Inflammation, Suppurative Epithelial Cell, Hyperplasia	(50) 8 (16%) (3) 1 (33%) (0) (50) (50) 1 (2%) 3 (6%) 8 (16%) (47) 40 (85%)	$(50) \\ 5 (10\%) \\ (5) \\ 1 (20\%) \\ 2 (40\%) \\ 1 (20\%) \\ (0) \\ (50) \\ (50) \\ 2 (4\%) \\ 6 (12\%) \\ 1 (2\%) \\ (50) \\ 42 (84\%) \\ 1 (2\%) \\ (50) \\ (2\%) \\ (50) $	(50) 7 (14%) (6) 1 (17%) 1 (17%) (1) (50) 6 (12%) 2 (4%) 4 (8%) 1 (2%) 1 (2%) (48) 43 (90%) 1 (2%)	(50) 1 (2%) (0) (50) 1 (2%) (50) 46 (92%) (47) 44 (94%)	
INTEGUMENTARY SYSTEM Mammary Gland Cyst Inflammation, Chronic	(50)	(50)	(49) 1 (2%) 1 (2%)	(50)	
Skin Hyperkeratosis Inflammation, Chronic Ulcer Subcutaneous Tissue, Inflammation, Granulomatous	(50)	(50) 1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%) 1 (2%)	(50)	

MUSCULOSKELETAL SYSTEM

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Bone Skeletal Muscle	(50) (1)	(50) (1)	(50) (1)	(50) (0)	
ERVOUS SYSTEM					
Brain Hydrocephalus	(50) 3 (6%)	(50)	(50)	(50)	
Cerebrum, Compression Hypothalamus, Compression		1 (2%)			
Neuron, Necrosis, Focal	1 (2%)		1 (2%)		
Peripheral Nerve Axon, Degeneration	(2) 1 (50%)	(0)	(0)	(0)	
ESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	
Inflammation Inflammation, Chronic	32 (64%) 1 (2%)	33 (66%)	18 (36%)	14 (28%)	
Metaplasia, Osseous Alveolar Epithelium, Hyperplasia	5 (10%) 9 (18%)	9 (18%)	1 (2%) 2 (4%)	2 (4%) 4 (8%)	
Alveolus, Emphysema	1 (2%)	× ,			
Nose Dysplasia	(50)	(50)	(50) 1 (2%)	(50)	
Inflammation, Chronic Active Ulcer	14 (28%)	19 (38%)	27 (54%) 1 (2%)	35 (70%)	
Olfactory Epithelium, Degeneration	45 (90%)	49 (98%)	47 (94%)	49 (98%)	
Trachea Peritracheal Tissue, Inflammation, Chronic	(50)	(50) 1 (2%)	(50)	(50)	
PECIAL SENSES SYSTEM					
Eye	(50)	(50)	(50)	(50)	
Cataract Anterior Chamber, Inflammation, Suppurative	1 (2%)	1 (2%)			
Cornea, Inflammation, Suppurative Retina, Degeneration		1 (2%) 1 (2%)			
Sclera, Metaplasia, Osseous Harderian Gland	23 (46%) (50)	25 (50%) (50)	30 (60%) (50)	6 (12%) (49)	
Atrophy		1 (2%)	(30)	1 (2%)	
Cyst Hyperplasia	1 (2%) 1 (2%)	2 (4%)		1 (2%)	
Inflammation, Chronic Pigmentation, Porphyrin	2 (4%) 50 (100%)	1 (2%) 50 (100%)	50 (100%)	2 (4%) 49 (100%)	

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Zymbal's Gland	(0)	(1)	(0)	(0)	
JRINARY SYSTEM					
Kidney Hydronephrosis	(50) 1 (2%)	(50)	(50)	(50)	
Inflammation, Suppurative, Focal Inflammation, Chronic	1 (2%) 1 (2%)	22 (44%)	22 (44%)		
Metaplasia, Osseous Mineralization		1 (2%)	1 (2%)		
Necrosis Nephropathy	1 (2%) 45 (90%)	2 (4%) 48 (96%)	2 (4%) 48 (96%)	49 (98%)	
Pigmentation	1 (2%)				
Papilla, Mineralization Renal Tubule, Cyst	1 (2%) 1 (2%)	48 (96%) 3 (6%)	40 (80%) 2 (4%)	4 (8%)	
Renal Tubule, Hyperplasia	. (=/0)		2 (4%)		
Renal Tubule, Hyperplasia, Oncocytic		3 (6%)			
Renal Tubule, Nephrosis		42 (84%)	46 (92%)	48 (96%)	
Transitional Epithelium, Hyperplasia Vein, Thrombosis		21 (42%)	19 (38%) 3 (6%)	18 (36%) 3 (6%)	
Urinary Bladder Inflammation	(50)	(50)	(50)	(49) 1 (2%)	

*** END OF MALE ***

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed Dosing Accident		1		1
Moribund Sacrifice	11	9	12	7
Natural Death	8	6	10	9
Survivors	24	22	00	22
Terminal Sacrifice Animals Examined Microscopically	31 50	33 50	28 50	33 50
	00			
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(49)	(50)
Perforation		1 (2%)		
Muscularis, Inflammation, Chronic	(50)	(50)	(50)	1 (2%)
Intestine Large, Colon Parasite Metazoan	(50)	(50) 1 (2%)	(50) 1 (2%)	(50)
Ulcer		· (2/0)	1 (2/0)	1 (2%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Parasite Metazoan	1 (2%)	5 (10%)	5 (10%)	2 (4%)
Ulcer Intestine Small, Duodenum	1 (2%) (50)	(50)	(49)	(50)
Intestine Small, Ileum	(50)	(50) (50)	(49)	(50)
Epithelium, Hyperplasia, Focal	(88)	(00)	(10)	1 (2%)
Liver	(50)	(50)	(49)	(50)
Angiectasis	1 (2%)	40 (000()	40 (000)	1 (2%)
Basophilic Focus Clear Cell Focus	44 (88%) 4 (8%)	43 (86%) 6 (12%)	42 (86%) 6 (12%)	31 (62%) 8 (16%)
Eosinophilic Focus	6 (12%)	10 (20%)	15 (31%)	24 (48%)
Fatty Change	3 (6%)	3 (6%)	4 (8%)	1 (2%)
Fibrosis	. ,		2 (4%)	
Hemorrhage	6 (400/)	1 (2%)	6 (400/)	0 (4 00/)
Hepatodiaphragmatic Nodule Inflammation, Chronic	6 (12%) 41 (82%)	5 (10%) 41 (82%)	6 (12%) 41 (84%)	8 (16%) 33 (66%)
Mineralization	41 (0270)	41 (0270)	1 (2%)	55 (0070)
Mixed Cell Focus	6 (12%)	5 (10%)	3 (6%)	6 (12%)
Necrosis	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Regeneration Bile Duct, Cyst	1 (2%)			1 (20/)
Bile Duct, Cyst Bile Duct, Hyperplasia	8 (16%)	11 (22%)	12 (24%)	1 (2%) 11 (22%)
Centrilobular, Degeneration	1 (2%)	11 (22/0)	2 (4%)	1 (2%)

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
			- /		
Centrilobular, Necrosis	4 (00/)		2 (4%)		
Sinusoid, Congestion Sinusoid, Infiltration Cellular, Histiocyte	1 (2%) 1 (2%)				
Mesentery	(7)	(13)	(7)	(9)	
Fat, Necrosis	6 (86%)	13 (100%)	7 (100%)	(9) 9 (100%)	
Oral Mucosa	(1)	(0)	(0)	(0)	
Pancreas	(50)	(50)	(49)	(50)	
Acinus, Atrophy	9 (18%)	9 (18%)	10 (20%)	3 (6%)	
Acinus, Hyperplasia	1 (2%)	9 (1078)	1 (2%)	5 (078)	
Duct, Cyst	3 (6%)	2 (4%)	3 (6%)	4 (8%)	
Salivary Glands	(50)	(49)	(49)	(50)	
Hyperplasia	(30)	(49)	(49)	1 (2%)	
Stomach, Forestomach	(50)	(50)	(49)	(50)	
Inflammation, Chronic Active	1 (2%)	1 (2%)	2 (4%)	3 (6%)	
Ulcer	1 (278)	1 (270)	1 (2%)	1 (2%)	
Stomach, Glandular	(50)	(50)	(49)	(50)	
Mineralization	1 (2%)	4 (8%)	(49)	1 (2%)	
Epithelium, Ectasia	38 (76%)	39 (78%)	36 (73%)	38 (76%)	
Epithelium, Hyperplasia	38 (70 %)	39 (7878)	30 (7378)	1 (2%)	
Tongue	(1)	(0)	(1)	(0)	
Tongue	(1)	(0)	(1)	(0)	
CARDIOVASCULAR SYSTEM					
Heart	(50)	(50)	(49)	(50)	
Cardiomyopathy	43 (86%)	31 (62%)	30 (61%)	34 (68%)	
Fibrosis		1 (2%)			
Atrium, Thrombosis			1 (2%)		
Myocardium, Inflammation, Chronic		1 (2%)			
Valve, Inflammation, Chronic		1 (2%)			
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Hyperplasia	10 (20%)	10 (20%)	12 (24%)	8 (16%)	
Necrosis	((1 (2%)	(),	
Vacuolization Cytoplasmic	17 (34%)	14 (28%)	14 (28%)	16 (32%)	
Adrenal Medulla	(50)	(50)	(50)	(50)	
Hyperplasia	3 (6%)	1 (2%)	4 (8%)	1 (2%)	
Islets, Pancreatic	(50)	(50)	(49)	(50)	
Hyperplasia		2 (4%)	4 (8%)		
Parathyroid Gland	(47)	(48)	(47)	(45)	
Cyst	. ,			1 (2%)	
Pituitary Gland	(50)	(50)	(50)	(50)	
Angiectasis	17 (34%)	24 (48%)	16 (32%)	14 (28%)	

TDMS No. 99023 - 03 Test Type: CHRONIC Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE	Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT			
FISCHER 344 RATS FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Cyst Fibrosis Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia Thyroid Gland	14 (28%) 1 (2%) 14 (28%) 1 (2%) (50)	22 (44%) 2 (4%) 13 (26%) (49)	16 (32%) 15 (30%) (49) 1 (2%)	9 (18%) 10 (20%) (50)	
Cyst C-cell, Hyperplasia Follicle, Hyperplasia	19 (38%) 1 (2%)	20 (41%) 1 (2%)	22 (45%) 4 (8%)	17 (34%) 4 (8%)	
GENERAL BODY SYSTEM					
GENITAL SYSTEM					
Clitoral Gland Cyst Hyperplasia Inflammation, Chronic Ovary Atrophy Cyst Uterus	(50) 3 (6%) 8 (16%) 22 (44%) (50) 3 (6%) (50)	(50) 1 (2%) 8 (16%) 11 (22%) (50) 1 (2%) 7 (14%) (50)	(50) 1 (2%) 13 (26%) 26 (52%) (50) 6 (12%) (50)	(50) 4 (8%) 14 (28%) (50) 4 (8%) (50)	
Angiectasis Cyst Dilatation Inflammation, Suppurative Inflammation, Chronic Necrosis Endometrium, Hyperplasia, Cystic	2 (4%) 1 (2%) 4 (8%)	2 (4%) 1 (2%) 1 (2%) 7 (14%)	2 (4%) 2 (4%) 1 (2%) 7 (14%)	1 (2%) 1 (2%) 1 (2%) 1 (2%) 13 (26%)	
HEMATOPOIETIC SYSTEM					
Bone Marrow Hyperplasia Lymph Node Deep Cervical, Hyperplasia, Lymphoid Deep Cervical, Infiltration Cellular, Histiocyte Deep Cervical, Pigmentation Mediastinal, Ectasia	(50) 3 (6%) (5) 1 (20%)	(50) 1 (2%) (3) 1 (33%) 2 (C77()	(50) 2 (4%) (2)	(50) 1 (2%) (6) 1 (17%) 1 (17%)	
Mediastinal, Hyperplasia, Lymphoid Lymph Node, Mesenteric Infiltration Cellular, Histiocyte	1 (20%) (50)	2 (67%) (50)	(50)	1 (17%) (50) 1 (2%)	

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 08/15/2008 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Pigmentation, Hemosiderin Spleen Atrophy Fibrosis Hematopoietic Cell Proliferation Infarct Thymus	(50) 6 (12%) 7 (14%) (49)	(50) 2 (4%) 12 (24%) (48)	(50) 3 (6%) 1 (2%) 13 (26%) 1 (2%) (49)	1 (2%) (50) 2 (4%) 9 (18%) (50)	
Átrophy Cyst Infiltration Cellular, Lymphocyte Inflammation, Chronic	46 (94%) 1 (2%)	(48) 45 (94%) 1 (2%)	47 (96%) 1 (2%)	(30) 44 (88%) 1 (2%)	
Epithelial Cell, Hyperplasia	1 (2%)		1 (2%)		
Mammary Gland Cyst Skin Cyst Epithelial Inclusion	(50) 2 (4%) (50)	(50) 1 (2%) (50) 1 (2%)	(50) 2 (4%) (50)	(50) 2 (4%) (50)	
MUSCULOSKELETAL SYSTEM					
Skeletal Muscle Inflammation, Suppurative	(0)	(0)	(1) 1 (100%)	(0)	
NERVOUS SYSTEM					
Brain Hydrocephalus Hypothalamus, Compression Meninges, Inflammation, Chronic Spinal Cord	(50) 3 (6%) 4 (8%) (1)	(50) 4 (8%) 4 (8%) (0)	(50) 6 (12%) 8 (16%) 1 (2%) (0)	(50) 2 (4%) 5 (10%) 2 (4%) (0)	
RESPIRATORY SYSTEM					
Lung Congestion Edema Inflammation Metaplasia, Osseous Alveolar Epithelium, Hyperplasia Nose	(50) 1 (2%) 34 (68%) 1 (2%) 6 (12%) (50)	(50) 1 (2%) 43 (86%) 3 (6%) (50)	(49) 40 (82%) 4 (8%) (50)	(50) 32 (64%) 2 (4%) 7 (14%) (50)	

T DMS No. 99023 - 03 Test Type: CHRONIC Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE	Date Report Requested: 08/15/2007 Time Report Requested: 14:01:25 First Dose M/F: 03/25/02 / 03/26/02 Lab: BAT			
FISCHER 344 RATS FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG	
Erosion Inflammation, Chronic Active Olfactory Epithelium, Degeneration	1 (2%) 16 (32%) 45 (90%)	10 (20%) 44 (88%)	13 (26%) 45 (90%)	10 (20%) 48 (96%)	
SPECIAL SENSES SYSTEM					
Ear Hyperplasia Eye Cataract Degeneration Optic Nerve, Atrophy Retina, Atrophy Sclera, Metaplasia, Osseous Harderian Gland Atrophy Hyperplasia Inflammation, Chronic Pigmentation, Porphyrin Zymbal's Gland	(0) (50) 1 (2%) 1 (2%) 1 (2%) (50) 1 (2%) 1 (2%) 7 (14%) 50 (100%) (0)	(3) 1 (33%) (50) 1 (2%) 8 (16%) 48 (96%) (0)	(0) (49) 1 (2%) 2 (4%) 1 (2%) 7 (14%) 48 (98%) (0)	(0) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) (50) 1 (2%) 2 (4%) 45 (90%) (2)	
URINARY SYSTEM	(50)	(50)	(50)	(50)	
Kidney Inflammation, Suppurative, Focal Mineralization Necrosis Nephropathy Pigmentation Papilla, Inflammation, Suppurative	(50) 1 (2%) 1 (2%) 26 (52%) 1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%) 43 (86%)	(50) 1 (2%) 41 (82%)	(50) 1 (2%) 44 (88%)	
Papilla, Inflammation, Supplicative Papilla, Mineralization Pelvis, Inflammation, Chronic Renal Tubule, Cyst Renal Tubule, Hyperplasia Renal Tubule, Nephrosis Transitional Epithelium, Hyperplasia Urinary Bladder Inflammation	1 (2%) 5 (10%) 1 (2%) 2 (4%) 1 (2%) (50) 2 (4%)	3 (6%) 3 (6%) 2 (4%) 12 (24%) (50)	1 (2%) 1 (2%) 27 (54%) 15 (30%) (50) 1 (2%)	1 (2%) 45 (90%) 19 (38%) (50)	

*** END OF REPORT ***